Researchers developed a platform where they assemble eight (chemical) building blocks by a simple process to make macrolide antibiotics - which inhibit the growth of bacteria - without using erythromycin, the drug upon which all others in the class have been based since the early 1950s.
Erythromycin, which was discovered in a soil sample from the Philippines in 1949, has been on the market as a drug by 1953.
"For 60 years chemists have been very, very creative, finding clever ways to 'decorate' this molecule, making changes around its periphery to produce antibiotics that are safer, more effective, and overcome the resistance bacteria have developed," said Andrew G Myers, professor at the Harvard University.
In contrast, the process described in the new study involves using "eight industrial chemicals, or substances derived from them," Myers said, and manipulating them in various combinations and then testing the products against panels of disease causing bacteria.
This allows us to make new new compounds in fewer steps than was previously possible, the researchers said.
"One of the things that's quite encouraging about the data in our paper is that some of the structures we've made are active against clinical bacterial strains that are resistant to every known macrolide," Myers said.
Some of the 350 compounds reported on in the study will undergo more extensive testing to evaluate their potential as candidate drugs.
The study was published in the journal Nature.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
